[Specific immunotherapies in the treatment of cancers].
Les immunothérapies spécifiques dans le traitement des cancers.
Antibodies, Monoclonal, Humanized
/ therapeutic use
B7-H1 Antigen
/ antagonists & inhibitors
CTLA-4 Antigen
/ antagonists & inhibitors
France
Humans
Immunotherapy
/ methods
Immunotherapy, Adoptive
/ methods
Ipilimumab
/ therapeutic use
Molecular Targeted Therapy
Neoplasms
/ therapy
Nivolumab
/ therapeutic use
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Receptors, Chimeric Antigen
Anti-CTLA
Anti-CTLA-4
Anti-PD-1
Anti-PD-L1
CAR-T cells
Cellules CAR-T
Immunotherapies
Immunothérapies
Medicines
Médicaments
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
25
10
2018
revised:
06
12
2018
accepted:
16
12
2018
pubmed:
15
1
2019
medline:
5
2
2019
entrez:
15
1
2019
Statut:
ppublish
Résumé
The offer of anti-cancer drugs has recently been disrupted by the introduction of checkpoint inhibitors on the market. Currently, one anti-CTLA-4, two anti-PD-1 and two anti-PD-L1 are authorized in the European Union, in seven different types of cancer. The clinical development of these therapies is still in full swing: in July 2017, more than 1 500 clinical trials were evaluating anti-PD-1, anti-PD-L1 and anti-CTLA-4 drugs in about twenty different locations and this number continues to increase. In the short term in France, other immunotherapies, the CAR-T cells, will complete this therapeutic arsenal. These immunotherapies appear as a real revolution in the treatment of some cancers. Nevertheless, many issues are associated with these therapies, particularly regarding the identification of good responders, the proper use of these drugs including the management of therapeutic strategies and safety profile, as well as the organization of care. In addition, the expenses associated with ipilimumab, nivolumab and pembrolizumab are substantial and almost tripled in one year, going from 120 million euros in 2015 to more than 340 million euros in 2016. This raises the question of the ability of the current healthcare system to maintain equitable access to innovation and best treatments for all patients. For all these reasons, the French National Cancer Institute decided to dedicate its thematic annual report on these innovative immunotherapies, targeting in particular checkpoint inhibitors and CAR-T cells, in order to produce an inventory of current data and an analysis regarding the different issues associated with these therapies.
Identifiants
pubmed: 30638899
pii: S0007-4551(18)30407-7
doi: 10.1016/j.bulcan.2018.12.007
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
B7-H1 Antigen
0
CD274 protein, human
0
CTLA-4 Antigen
0
CTLA4 protein, human
0
Ipilimumab
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Receptors, Chimeric Antigen
0
Nivolumab
31YO63LBSN
pembrolizumab
DPT0O3T46P
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
37-47Informations de copyright
Copyright © 2018 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.